568 Bibliografia [1] Tucci F, Scaramuzza S, Aiuti A, Mortellaro. Update on Clinical Ex Vivo Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases. Mol Ther. 2021 Feb 3;29(2):489-504. doi: 10.1016/j. ymthe.2020.11.020 [2] Ferrari G, Thrasher AJ, Aiuti A. Gene therapy using haematopoietic stem and progenitor cells. Nat Rev Genet 2021;22(4):216-34. doi:10.1038/s41576-020-00298-5 [3] Fraldi A, Serafini M, Sorrentino NC, Gentner A, Aiuti A, Bernardo ME. Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches. Ital J Pediatr 2018 Nov 16;44(Suppl 2):130. doi: 10.1186/ s13052-018-0565-y [4] Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 2001 Jan;7(1):33-40. doi: 10.1038/83324 [5] Hastie E & Samulski RJ. Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective. Hum Gene Ther. 2015 May;26(5):257-65. doi: 10.1089/hum.2015.025 [6] Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013 Aug 23;341(6148):1233158. doi: 10.1126/science.1233158 [7] Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C, et al. Lentiviral hematopoietic stem and progenitor cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, opne-label, phase 1/2 trial. Lancet. 2016 Jul 30;388(10043):476-87. doi: 10.1016/S0140-6736(16)30374-9 [8] Gentner B, Tucci F, Galimberti S, Fumagalli F, De Pellegrin M, Silvani P, et al. Hematopoietic stem- and progenitor- cell gene therapy for Hurler syndrome. N Engl J Med. 2021 Nov 18;385(21):19291940. doi: 10.1056/NEJMoa2106596 [9] Fumagalli F, Calbi V, Natali Sora MG, Sessa M, Baldoli C, Rancoita PMV, et al. Lentiviral hematopoietic stem and progenitor cell gene therapy in early-onset metachromatic leukodystrophy: longterm results from a non-randomised, opne-label, phase 1/2 trial and expanded access. Lancet. 2022 Jan 22;399(10322):372-383. doi: 10.1016/S0140-6736(21)02017-1 [10] Migliavacca M, Barzaghi, F, Fossati, C, Garella, V, Dionisio, F, Giannelli, S, et al. Experience With The First Approved Commercial Gene Therapy For The Treatment Of Severe Combined Immunodeficiency Due To Adenosine Deaminase Deficiency (ADA-SCID). 19th Biennial Meeting of The European Society for Immunodeficiencies Online meeting 2020 [11] Aiuti A, Pasinelli F, Naldini L. Ensuring a future for gene therapy for rare diseases. Nat Med. 2022 Aug 15. doi: 10.1038/s41591-02201934-9 [12] Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Trasher AJ, Hongeng S, et al. Betibeglogene Autotemcel Gene Therapy for Non-beta(0)/beta(0) Genotype beta-Thalassemia. N Engl J Med 2022 Feb 3;386(5):415-427. doi: 10.1056/NEJMoa2113206 [13] Cicalese MP, Aiuti A. Clinical applications of gene therapy for primary immunodeficiencies. Hum Gene Ther 2015;26(4):210-9. doi: 10.1089/hum.2015.047 [14] Cavazzana M, Bushman FD, Miccio A, Andrè-Schmutz A, Six E. Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges. Nat Rev Drug Discov 2019;18(6):447-62. doi: 10.1038/s41573-019-0020-9 [15] Six E GV, Magnani A, et al. LMO2 Associated Clonal T Cell Proliferation 15 Years After Gamma-Retrovirus Mediated Gene Therapy for SCIDX1. Molecular Therapy 2017;25 [16] Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S, et al. A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. NEngl J Med 2014;371(15):140717. doi: 10.1056/NEJMoa1404588 [17] Malech HL, Wu X, Kang E, et al. Enhanced Transduction Lentivector Gene Therapy for Treatment of Older Patients with X-Linked Severe Combined Immunodeficiency. Blood 2019;134(Supplement_1):608-08. doi: 10.1182/blood-2019-127439 [18] De Ravin SS, Wu X, Moir S, Anaya-O'Brien S, Kwatemaa N, Littel P, et al. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2016 Apr 20;8(335):335ra57. doi: 10.1126/scitranslmed.aad8856 [19] Mamcarz E, Zhou S, Lockey T, Abdelsamed H, Cross SJ, Kang G, et al. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. N Engl J Med 2019;380(16):1525-34. doi: 10.1056/ [published Online First: 2019/04/18] [20] Bradford KL, Moretti FA, Carbonaro-Sarracino DA, Gaspar HB, Kohn DB. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations. J Clin Immunol 2017;37(7):626-37. doi: 10.1007/s10875017-0433-3 [21] Chan B, Wara D, Bastian J, Hershfield MS, Bohnsack J, Azen CG, et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol 2005;117(2):133-43. doi: 10.1016/j. clim.2005.07.006 [22] Kohn DB, Hershfield MS, Puck JM, Aiutti A, Blincoe A, Gaspar HB, et al. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol 2019;143(3):852-63. doi: 10.1016/j. jaci.2018.08.024 [23] Barzaghi F, Migliavacca, M, Fossati, C, Recupero, S, Pajno, R, Giannelli, S, et al. . Ex Vivo Retroviral Gene Therapy For The Treatment Of Severe Combined Immunodeficiency Due To Adenosine Deaminase Deficiency (ADA-SCID): Long-Term (Up To 18 Years) Follow-Up. 19th Biennial Meeting of The European Society for Immunodeficiencies Online meeting 2020 [24] Cicalese MP, Ferrua F, Castagnaro L, Pajno R, Barzaghi F, Giannelli S, Dionisio F, Brigida I, Bonopane M, Casiraghi M, Tabucchi A, Carlucci F, Grunebaum E, Adeli M, Bredius RG, Puck JM, Stepensky P, Tezcan I, Rolfe K, De Boever E, Reinhardt RR, Appleby J, Ciceri F, Roncarolo MG, Aiuti A. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood 2016 Jul 7;128(1):45-54. doi: 10.1182/ blood-2016-01-688226 [25] Kohn DB, Booth C, Shaw KL, Xu-Bayford J, Garabedian E, Trevisan V, et al. Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency. N Engl J Med 2021;384(21):2002-13. doi: 10.1056/NEJMoa2027675 [26] Candotti F. Clinical manifestations and pathophysiological mechanisms of the Wiskott-Aldrich syndrome. J Clin Immunol. 2018; 38: 13-27. doi: 10.1007/s10875-017-0453-z [27] Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, et al. Gene therapy for Wiskott-Aldrich syndrome--longterm efficacy and genotoxicity. Sci Transl Med 2014;6(227):227ra33. doi: 10.1126/scitranslmed.3007280 [28] Ferrua F, Cicalese MP, Galimberti S, Giannelli S, Dionisio F, Barzaghi F, et al. Lentiviral hematopoietic stem/progenitori cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomise, open-label, phase 1/2 clinical study. Lancet Haematol. 2019 May;6(5):e239-e253. doi: 10.1016/S23523026(19)30021-3 [29] Ferrua F, Marangoni F, Aiuti A, Roncarolo MG. Gene therapy for Wiskott-Aldrich syndrome: History, new vectors, future directions. J Allergy Clin Immunol 2020;146(2):262-65. doi: 10.1016/j. jaci.2020.06.018 [30] Magnani A, Semeraro M, Adam F, Booth C, Duprè L, Morris EC, et al. Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott–Aldrich syndrome. Nature Medicine 2022;28(1):71-80. doi: 10.1038/s41591-021-01641-x [31] Morris EC, Fox T, Chakraverty R, Tendeiro R, Snell K, Rivat C, et al. Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. Blood 2017;130(11):1327-35. doi: 10.1182/blood-2017-04-777136 [32] Chiesa R, Wang J, Blok HJ, Hazelaar S, Neven B, Moshous D, et al. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood. 2020 Sep 3;136(10):1201-1211. doi: 10.1182/blood.2020005590 [33] Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 2006 Apr;12(4):401-9. doi: 10.1038/ nm1393. [34] Kang HJ, Bartholomae CC, Paruzynski A, Arens A, Kim S, Yu SS, et al. Retroviral gene therapy for X-linked chronic granulomatous
RkJQdWJsaXNoZXIy ODUzNzk5